Comparing HIV Vaccine Immunogenicity across Trials with Different Populations and Study Designs

Yutong Jin,Alex Luedtke,Zoe Moodie,Holly Janes,David Benkeser

DOI: https://doi.org/10.48550/arXiv.2410.05594

2024-10-08

Abstract:Safe and effective preventive vaccines have the potential to help stem the HIV epidemic. The efficacy of such vaccines is typically measured in randomized, double-blind phase IIb/III trials and described as a reduction in newly acquired HIV infections. However, such trials are often expensive, time-consuming, and/or logistically challenging. These challenges lead to a great interest in immune responses induced by vaccination, and in identifying which immune responses predict vaccine efficacy. These responses are termed vaccine correlates of protection. Studies of vaccine-induced immunogenicity vary in size and design, ranging from small, early phase trials, to case-control studies nested in a broader late-phase randomized trial. Moreover, trials can be conducted in geographically diverse study populations across the world. Such diversity presents a challenge for objectively comparing vaccine-induced immunogenicity. To address these practical challenges, we propose a framework that is capable of identifying appropriate causal estimands and estimators, which can be used to provide standardized comparisons of vaccine-induced immunogenicity across trials. We evaluate the performance of the proposed estimands via extensive simulation studies. Our estimators are well-behaved and enjoy robustness properties. The proposed technique is applied to compare vaccine immunogenicity using data from three recent HIV vaccine trials.

Methodology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to objectively compare vaccine - induced immunogenicity among HIV vaccine trials in different populations and research designs. Specifically, the authors propose a framework for identifying appropriate causal estimators and estimators to provide a standardized comparison of vaccine - induced immunogenicity. The following are the core problems of the paper and their solutions:

### Core problems:
1. **Differences in the design and population of different trials**: Different HIV vaccine trials may have significant differences in geographical regions, trial designs, and subject characteristics, which makes it difficult to directly compare immunogenicity in different trials.
2. **Causality of immunogenicity**: It is necessary to understand the causal relationship between the vaccine regimen and immunogenicity in specific populations in order to guide the design of new vaccines and the prioritization of existing vaccines.

### Solutions:
1. **Propose a causal inference framework**: The authors propose a causal inference framework to provide a standardized comparison of vaccine - induced immunogenicity by identifying appropriate causal estimators and estimators.
2. **Handle different sampling designs**: This framework takes into account different sampling designs (e.g., case - control design) that may be used in different trials and provides corresponding estimation methods.
3. **Data merging**: Allows data to be merged when evaluating the same vaccine in multiple trials to improve efficiency.
4. **Theoretical basis**: A theoretical framework has been established to describe the large - sample behavior of estimators and ensure the robustness of estimators.

### Formula representation:
The formulas involved in the paper are presented in Markdown format as follows:

- Set the causal consistency assumption: \[ S(a) \] represents the immune response observed if an individual receives vaccine \( a \).
- Estimator of the average immune response: \[ \mu_a := E_X(S | A = a, T = t) \]
- Definition of the causal estimator: \[ \psi_X(a) = E_X[S(a) | T \in T_{\text{ref}}] \]
- Estimator under identification conditions: \[ \psi_X(a) = E_X[E_X(S | A = a, W_S) | T \in T_{\text{ref}}] \]

### Summary:
By introducing a causal inference framework, this paper addresses the challenge of objectively comparing vaccine - induced immunogenicity among HIV vaccine trials in different populations and research designs. This method not only helps to understand the causal relationship between the vaccine regimen and immunogenicity in specific populations, but also provides important guidance for future vaccine research and development.